Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase.
Thomas P. Kasten(Northwestern University), G. Allen Nickols(Monsanto (United States)), Philip Osdoby(Washington University in St. Louis), Thomas P. Misko(Monsanto (United States)), Steven L. Settle(Monsanto (United States)), Marilyn Krukowski(Monsanto (United States)), Patricia Collin‐Osdoby(University of Missouri–St. Louis), Mark G. Currie(Ironwood Pharmaceuticals (United States)), Nikhil Patel(Monsanto (United States))
Cited by 243
Related Papers
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine
|European Journal of Pharmacology|1993|727
Molecular Docking and High-Throughput Screening for Novel Inhibitors of Protein Tyrosine Phosphatase-1B
|Journal of Medicinal Chemistry|2002|467
Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis
|Journal of Biological Chemistry|2001|399
Analysis of the phosphofructokinase subunits and isoenzymes in human tissues
|Biochemical Journal|1988|157
Kinetic Characterization of Human Glutamine-fructose-6-phosphate Amidotransferase I
|Journal of Biological Chemistry|2002|105